News & Announcements

Bicycle Therapeutics in-conversation with JLL

30 June 2022

Hear how the demand profile of life science companies changes as their businesses mature, and how real estate decisions are now primarily based on the desires and needs of employees in the post-pandemic world.

Read More

Investor conference returns in new hybrid format

30 June 2022

We were delighted to welcome over 70 investors back to the Campus for the Investor Conference, which was also streamed online to over 50 viewers.

Read More

Female leaders join bit.bio with COO ‘proud of team we’re building’

24 June 2022

Kathryn Corzo took up the role of chief operating officer (COO) at synthetic biology company bit.bio in November.

Read More

Transine Therapeutics poised for growth with new CSO hire and tripling of lab space

23 June 2022

Transine Therapeutics today announced the appointment of Andy Billinton as Chief Scientific Officer as it triples its facility footprint at The Babraham Research Campus.

Read More

Dr Simon Cook appointed Institute Director

09 June 2022

The Board of Trustees is delighted to announce that Dr Simon Cook has been appointed as the Institute’s Director.

Read More

Transine Therapeutics Ltd closes £13.7m seed financing

01 June 2022

Company adds £4.6m additional seed funding. Strengthens investor syndicate with Epidarex joining as a new investor. Enhances ability to leverage unique SINEUP® platform and rapidly advance product development programmes.

Read More

Five Cambridge companies in inaugural Growth Index study

01 June 2022

Five Cambridge companies have made it to the inaugural Growth Index, a ranking of the fastest growing companies in the UK based on a rigorous financial analysis of the compound annual growth of 32,000 companies.

Read More

Babraham Institute launches a new digital look

23 May 2022

There’s a fresh new look to the Babraham Institute’s website, click here to see the lighter, brighter and improved digital experience.

Read More

New Building Development B960 - Archaeology Works on site 19th May to 8th July 2022

19 May 2022

Over the next eight weeks the Cambridge Archaeological Unit (CAU) will be undertaking an archaeological investigation of the site for our new development plot (B960). There may be some noise for tenants close by.

Read More

NVIDIA brings Alchemab into the Cambridge-1 supercomputer project

19 May 2022

Cambridge biotech pioneer Alchemab Therapeutics has been chosen by US tech giant NVIDIA to harness the power of  the UK’s most powerful supercomputer, Cambridge-1. 

Read More

15% off Cambs Cuisine

17 May 2022

Discount at CambsCuisine for all Babraham Research Campus staff

Read More

Benefits of plants in the office

17 May 2022

Why are plants so good for us in our workspace? The Good Plant Company can tell us why, including how you can work with them to improve your office.

Read More

Ongoing works to improve the River

17 May 2022

Major work has just been completed the river to improve habitat for wildlife, provide a better view of the river for walkers and improve the ability of the river to cope with floods and droughts.

Read More

Covid-19 Vaccination Bus

16 May 2022

Covid-19 Vaccination Walk-in Clinic, Monday 16th May 2022 between 9am – 3pm.

Read More

Cambridge Independent Science & Technology Awards

12 May 2022

Delighted to see so many companies and Accelerate at Babraham alumni being recognised at the recent awards ceremony.

Read More

Sphere Fluidics strengthens commercial team with three new senior hires

12 May 2022

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed three new hires to its commercial team.

Read More

Bicycle Therapeutics confident in its cash pile and portfolio

12 May 2022

Bicycle Therapeutics is progressing a robust oncology portfolio and has cash and equivalents of $407.4 million to provide a financial runway through 2024.

Read More

Cambridge company’s disease model sheds new light on Huntington’s

11 May 2022

A new disease model – one of the first of its kind to be made commercially available – is being hailed as a key pathfinder in reflecting the genetics of Huntington’s disease.

Read More

Maxion Therapeutics strengthens its Board

05 May 2022

Maxion Therapeutics today announced the appointment of Ian Tomlinson, PhD, Tom Weaver, PhD and Aneesh Karatt Vellatt, PhD, to the board of directors.

Read More

STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme

05 May 2022

STORM Therapeutics today announces that it has been awarded a Biomedical Catalyst grant by Innovate UK.

Read More

Abzena shows sixth sense with California expansion

05 May 2022

Life science power player Abzena, whose global headquarters is at Babraham Research Campus in Cambridge, has added a sixth site to its global operations network with expansion in California.

Read More

BBSRC Business and Academia Prosperity Partnership

05 May 2022

The BBSRC have released an £11m grant fund to support established research partnerships between business and academic institutions.

Read More

Assessing Life Sciences Skill Requirements in the Oxford Cambridge Arc

03 May 2022

Whitecap Consulting has been appointed by The Open University to research and analyse workforce skills and associated requirements in the growing Life Sciences sector in the Oxford-Cambridge Arc to 2030.

Read More

Nature Subscription: 45% discount for the world famous journal

28 April 2022

Exclusive discount offer for Babraham Research Campus tenants to the world-famous scientific journal Nature.

Read More

Supporting Cambridge's Life Sciences Ecosystem: Q&A With James Seppala and Tim Schoen

28 April 2022

James Seppala and Tim Schoen discuss BioMed Realty’s footprint in the UK and the opportunity in the life sciences real estate market in the years ahead.

Read More

Cambridge irons out the wrinkles in anti-ageing science arena

25 April 2022

Cambridge is playing a lead role in developing technology designed to rejuvenate skin cells and arrest the march of age-related diseases.

Read More

How Adrestia Therapeutics is pioneering synthetic rescue - an interview with Prof Steve Jackson and CEO Robert Johnson

19 April 2022

A new approach to tackling genetic diseases could unlock treatments to some of the most intractable conditions, it is hoped.

Read More

Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation

11 April 2022

Artios announces that the development of its ataxia telangiectasia and Rad3-related (“ATR”) Inhibitor, ART0380, has progressed into a Phase 1b dose expansion study targeting ATM deficient tumors.

Read More

Old skins cells reprogrammed to regain youthful function. Findings could lead to targeted approach for treating ageing

08 April 2022

Research from the Babraham Institute has developed a method to ‘time jump’ human skin cells by 30 years, turning back the ageing clock for cells without losing their specialised function.

Read More

From ‘a metaphorical slap around the face’ to ‘life-saving’ - how life science start-ups view Accelerate@Babraham

04 April 2022

The latest cohort of five life science start-ups to complete the 2021/22 cycle of Accelerate at Babraham may have had the added pressure of a pandemic throughout the five-month programme but all made great strides to develop their business propositions, which in turn promises to change patient outcomes.

Read More

Inivata and Collaborators Publish Clinical Validation Data for RaDaR™ Assay in Non-Small Cell Lung Cancer

24 March 2022

Inivata today announced the publication of new data in support of its RaDaR™ liquid biopsy test in patients with early-stage non-small cell lung cancer (NSCLC).

Read More

Alchemab selected to access NVIDIA Cambridge-1 supercomputer to advance machine learning enabled antibody discovery

24 March 2022

Alchemab Therapeutics has been selected by NVIDIA to harness the power of the UK’s most powerful supercomputer, Cambridge-1.

Read More

US showcase for novel app+drug hypertension treatment

24 March 2022

Data from a clinical trial on a new hypertension drug produced by Cambridge company Closed Loop Medicine will be presented to a scientific summit in Washington DC in early April.

Read More

Drug identified by BenevolentAI shown to reduce deaths in patients hospitalised by Covid-19

11 March 2022

A therapy identified using artificial intelligence has been shown to reduce deaths in patients hospitalised with Covid-19 by 13 per cent.

Read More

Volunteers help plant community forest garden with edible plants at Babraham Research Campus

03 March 2022

A community forest garden full of edible plants is being created within the estate of Babraham Research Campus, thanks to council funding and the work of volunteers.

Read More

Accelerate@Babraham alumni, Shift Bioscience is hiring!

21 February 2022

The longevity biotech company using machine learning to develop therapeutics for safe cellular reprogramming has three open positions.

Read More

‘Globally important’ Babraham Research Campus given go ahead to expand

25 January 2022

The Babraham Research Campus – one of the UK’s leading locations supporting early-stage bioscience enterprise – has been given the go ahead to expand, to ensure the UK life science research and development sector can continue to deliver world-changing health solutions.

Read More

We must rethink PhDs to smash barriers and ensure bioscience success

21 January 2022

Redesigning PhD training will help develop commercially savvy researchers, address skills gaps in UK bioscience and bolster innovation, say Simon Cook and Derek Jones.

Read More

There is still time to enter the CambridgeshireLive Business Excellence Awards 2022

19 January 2022

Entries for the awards close on Friday 21 January!

Read More

PetMedix enters into antibody discovery collaboration with Zoetis

13 January 2022

PetMedix™ is pleased to announce a collaboration with Zoetis to develop novel, fully species-specific companion animal monoclonal antibody therapeutics (mAbs) using PetMedix’s proprietary transgenic platforms.

Read More

BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies

13 January 2022

BioNTech and Crescendo Biologics today announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases.

Read More

LoQus23 Therapeutics raises £7m in seed round to propel work on Huntington’s disease treatments

29 November 2021

Oral small molecule specialist LoQus23 Therapeutics has successfully closed its £7million extended seed round to drive forward its work on new treatments for Huntington’s disease.

Read More

Sphere Fluidics closes $40m investment round to fund international expansion of Cyto-Mine technology

04 November 2021

Sphere Fluidics has closed a $40million (around £30m) investment round to expand its international sales activities.

Read More

Enterprising Minds: Man on a Mission

29 October 2021

An interview with Steve Jackson, Founder and former CSO of Mission Therapeutics; Founder, CSO and Interim CEO of Adrestia Therapeutics.

Read More

BenevolentAI aims to enter clinic in 2023 with candidate for novel ulcerative colitis target

27 October 2021

BenevolentAI has been buoyed by a significant milestone for its artificial intelligence-driven drug discovery platform.

Read More

Crescendo Biologics announces that Zai Lab has achieved proof-of-concept for ZL-1102 (Humabody®, CB001) in a Phase 1b clinical trial in psoriasis patients

27 October 2021

Crescendo Biologics today announces that Zai Lab has reported positive topline results from a randomized, double-blind, placebo-controlled Phase 1b proof-of-concept study of ZL-1102, an anti-IL-17A targeting Humabody®.

Read More

bit.bio expands Board of Directors with appointment of entrepreneurs and Nobel Laureate

27 October 2021

Today bit.bio welcomed three new members to its Board of Directors, who bring their respective experience of turning world class science into new industries and company growth.

Read More

Bicycle Therapeutics wheels in $201.3m growth capital

25 October 2021

Transatlantic biotech game-changer Bicycle Therapeutics is wowing NASDAQ with its 12-month performance and fundraising magic.

Read More

TRx Biosciences launched with blessing of Yusuf Hamied and Babraham Research Campus

15 October 2021

Robin Bannister, TRx Biosciences’ CEO, said Cipla chairman Dr Yusuf Hamied is “a super investor to have on board” at the launch of TRx Biosciences on Babraham Research Campus yesterday.

Read More

Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial

14 October 2021

Bicycle Therapeutics today provided a clinical update of its wholly-owned, next-generation Bicycle Toxin Conjugates (BTCs).

Read More

Mission Therapeutics Awarded Follow-On Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation

14 October 2021

Mission Therapeutics announced today that it has been awarded a Therapeutic Pipeline Program grant of approximately 0.5M USD from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Read More

Lucy Cavendish College launches innovative and unique Life Sciences Community

24 September 2021

The supportive and inclusive collaboration will provide new opportunities for STEMM students and improve employment prospects.

Read More

CC Bio aims to improve health of millions of women and cystic fibrosis patients with microbiome editing technology

24 September 2021

The lives of millions of women around the world could be improved by extraordinary microbiome editing technology pioneered by synthetic biology start-up CC Bio.

Read More

Huntington’s disease progression stopped in cell study by University of Cambridge and UCL researchers

08 September 2021

Exciting progress has been made in the lab in the fight against Huntington’s disease. Scientists at the University of Cambridge and UCL have identified a mechanism that stops its progression in cells.

Read More

All (name) change at the Babraham Research Campus

06 September 2021

Babraham Bioscience Technologies Ltd, which manages and develops the Babraham Research Campus on behalf of its shareholders - BBSRC and the Babraham Institute – is now known as Babraham Research Campus Ltd.

Read More

Bacteria blitzer CC Bio wins £890k to fast-track personalised cures

27 August 2021

Award-winning synthetic biology start-up CC Bio has raised £890,000 seed funding from Cambridge-based CMS Ventures to accelerate development of its innovative approach to infection treatment and prevention.

Read More

Cambridge Judge Business School are launching a new programme focusing on sustainability

26 August 2021

Would you like to be a part of the first ever Venture Creation: Sustainability cohort. Participation in the programme will help delegates develop their capacity for future innovation in addition to an entrepreneurial mindset that will support them throughout their career choices.

Read More

Ignite Founders’ Challenge - backing the next generation of early-stage entrepreneurs

26 August 2021

Judge Business School are delighted to announce Ignite Founder's Challenge starting in the Autumn term - is now open for applications. A specially designed four-week online programme for early-stage startups that consists of workshops and coaching sessions to transform your idea into a reality.

Read More

New technologies and early-stage ideas are needed for EnterpriseTECH student projects

26 August 2021

Judge Business School have an exciting opportunity for inventors. Would you like to find out if your early-stage research results or new or novel technology has commercial potential? Applications are open to submit project proposals for student teams to work on. The deadline for submissions is 6th September 2021.

Read More

Mission Therapeutics earns $20m milestone payment from AbbVie in Alzheimer’s and Parkinson’s collaboration

12 August 2021

Mission Therapeutics will receive a $20million milestone payment from AbbVie after two targets progressed to the next stage of drug discovery in their neurodegenerative disease collaboration.

Read More

Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X

06 August 2021

Artios Pharma today announced the completion of a US$153 million (£110 million) Series C financing to fund further development of its promising clinical-stage pipeline.

Read More

Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

06 August 2021

Bicycle Therapeutics today reported financial results for the second quarter ended June 30, 2021 and provided recent corporate updates.

Read More

DefiniGEN Achieves ISO 9001: (2015) Certification

04 August 2021

DefiniGEN, a provider of iPSC-derived products and disease modelling services, today announces that the company has earned ISO 9001: 2015 certification at its Cambridge UK facility.

Read More

PetMedix monoclonal antibodies outperform benchmarks in canine study

27 July 2021

Successful performance of first-ever fully canine antibodies in dog trial paves the way for next-generation technology to meet therapeutic needs in fast­growing pet health market.

Read More

Enabling Interaction

15 July 2021

Our CEO, Derek Jones speaks to UKSPA’s BreakThrough magazine about the history, evolution and achievements of the life sciences’ community at the Babraham Research Campus.

Read More

Over £200m invested in Babraham Campus companies in last year – but what lies ahead?

15 July 2021

The Babraham Investor Conference 2021 (BIC), an event for investors focusing on early-stage and scale-up life science and med-tech companies, moved online for the first time in its 15-year history.

Read More

Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis

14 July 2021

Bicycle Therapeutics today announced that Ionis Pharmaceuticals has exercised its option and entered into an exclusive worldwide license and collaboration agreement.

Read More

F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors

14 July 2021

F-star Therapeutics today announced that it has entered into an exclusive licensing agreement with AstraZeneca.

Read More

Adrestia Therapeutics in overdrive as it hires from new Cambridge HQ

14 July 2021

Cambridge life science business Adrestia Therapeutics is scaling fast as it accelerates its mission to rebalance disease and restore health.

Read More

New breast cancer drug could be ready within five years

14 July 2021

The treatment has been created by scientists at Cancer Research UK and Artios, a spin-out it set up in Cambridge to develop the drug which has received £90 million of funding.

Read More

Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.

14 July 2021

BenevolentAI announces the appointment of Dr François Nader as Chairman.

Read More

Cycling Plus: Investing in Cambridge's Active Travel Network

06 July 2021

The Greater Cambridge Partnership (GCP) has launched a consultation on active travel and possible corridors for investment and would like to hear from you.

Read More

BI offering free FlowJo courses to the Campus in July

01 July 2021

The Babraham Flow Cytometry Facility will be giving some free virtual FlowJo courses at the end of July to FlowJo site license holders and all Babraham Campus staff.  They will be offering an options for beginners and advanced users.

Read More

Kymab Release A New Video on Life at Kymab

24 June 2021

Kymab have released a new video on their website, showing us what life at Kymab is like. Looking at careers and also featuring Babraham Research Campus.

Read More

L'Oreal Research and Innovation looking to explore technology start-ups this September & October

18 June 2021

The Open Innovation Department of L’Oréal Research and Innovation is working with the Cambridge Network to plan a virtual event during which they hope to explore innovative deep tech start-ups, and incubators and accelerators. For more information and to get involved please read more...

Read More

Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications

18 June 2021

Artios Pharma today announced the publication of a peer reviewed article titled, “Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance” in Nature Communications.

Read More

PetMedix announces completion of the Ky9™ canine antibody discovery platform

17 June 2021

Scientists working in the labs of PetMedix Ltd have recently achieved the successful transfer of more than 4 Mbp of canine antibody DNA into the mouse genome.

Read More

Transine Therapeutics’ £9.1m will drive forward RNA therapeutics

14 June 2021

Despite progress in understanding the functions of novel long non-coding RNAs, their applications as therapeutic tools have been very limited – but that’s about to change thanks to a £9.1million seed round for Transine Therapeutics.

Read More

Inivata Announces Collaboration with F-star Therapeutics for the use of RaDaR™ Assay

27 May 2021

Inivata today announced a collaboration with F-star Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, for the use of Inivata’s RaDaR technology.

Read More

Babraham Institute: a new algorithm streamlines and improves flow cytometry analysis

17 May 2021

The new algorithm provides a fast and effective way to reduce errors in flow cytometry data analysis, overcoming a major restriction on harnessing the full potential of the power of flow cytometry in cell analysis.

Read More

Kalium Health appoints Kenneth Galbraith as Chair of the Board

13 May 2021

Kalium Health Ltd, which is working to help millions of people living with kidney disease and related conditions to manage their health at home, is pleased to announce the appointment of Kenneth Galbraith as Chair of the Board.

Read More

Professor Adrian Liston, Babraham Institute, and Dr Jane Osbourn OBE, Alchemab, elected to prestigious Academy of Medical Sciences Fellowship

12 May 2021

Today the Academy of Medical Sciences have announced 50 outstanding biomedical and health scientists to their Fellowship.

Read More

Alchemab raises £60 million in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics

16 April 2021

Alchemab Therapeutics today announces the completion of a £60 million ($82 million) Series A financing round.

Read More

CamBioScience & Merck: Modern PCR & NGS Methods of Clinical Relevance

08 April 2021

CamBioScience has partnered with Merck Life Sciences to provide an exciting, free online course on Modern PCR & NGS Methods of Clinical Relevance.

Read More

Artios clinches minimum $1.5bn from Novartis for cancer assault

07 April 2021

Artios Pharma, based on the Babraham Research Campus in Cambridge, has clinched a megabucks deal with Novartis that is worth at least $1.5 billion and promises fresh assaults on cancers.

Read More

The 25 Best Biotech Incubators Hatching Startup Stars in Europe

06 April 2021

Incubators can give biotech startups the boost they need to get off the ground. Accelerate@Babraham has made Labiotech's top 25 biotech incubators across Europe supporting the next generation of life science startups.

Read More

UKRI publishes their AI Review: Transforming our world with AI

06 April 2021

The AI review ’Transforming our world with AI’ sets out UKRI’s view of the opportunities for research and innovation in AI – artificial intelligence – in the UK.

Read More

Closed Loop Medicine completes recruitment into clinical study that is required for regulatory submission of its insomnia product CLM-IN01

01 April 2021

Closed Loop Medicine announces that it has completed recruitment for its critical clinical trial in the development of its combination product CLM-IN01 for insomnia.

Read More

F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update

01 April 2021

F-star Therapeutics today announces 2020 full-year financial results and provides corporate update.

Read More

Mission Therapeutics Welcomes Co-founder of Rosetta Capital, Jonathan Hepple, to its Board of Directors

25 March 2021

Mission Therapeutics today announces the appointment of Jonathan Hepple to the Company’s Board as a Non-Executive Director.

Read More

Kalium Health announces funding from National Institute for Health Research

23 March 2021

Kalium Health today announces it has been awarded funding by the National Institute for Health Research (NIHR).

Read More

Axol and CENSO unveil merger and $5.3m investment

18 March 2021

Cell technology specialists Axol Bioscience and CENSO Biotechnologies have agreed to merge and announced an associated investment round of more than $5.3 million led by Calculus Capital and Par Equity.

Read More

Welsh startup Antiverse raises $2m for antibody discovery toolkit

16 March 2021

New biotech Antiverse has raised seed funding of £1.4 million ($2 million) to develop its artificial intelligence-based platform for discovering therapeutic antibodies.

Read More

Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model

17 February 2021

Founded by Medicxi, Centessa Pharmaceuticals launched today as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs.

Read More

Leading clinical immunotherapies developer Ramy Ibrahim joins bit.bio as Chief Medical Officer

17 February 2021

Biotech firm bit.bio today announces the appointment of Dr Ramy Ibrahim, MD, as Chief Medical Officer. The addition of a Chief Medical Officer is in line with the company’s plans and commitment to transition into a clinical company.

Read More

BenevolentAI Announces First Patient Dosed In Its Atopic Dermatitis Clinical Trial

17 February 2021

BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis.

Read More

Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients

12 February 2021

Artios Pharma today announced the start of a clinical trial of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumors.

Read More

Inivata takes Series C to $60m with fresh $35m raise

09 February 2021

Cambridge liquid biopsy business Inivata has raised $35 million in a second close of a Series C financing round. 

Read More

PredictImmune establishes IBD Clinical Advisory Board to advise on European access to PredictSURE IBD™

02 February 2021

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is pleased to confirm the convening of its IBD Clinical Advisory Board (IBD CAB).

Read More

F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1

27 January 2021

F-star Therapeutics today announces the European Patent Office (EPO) has granted a patent with claims protecting the composition of matter of F-star’s FS118 molecule throughout Europe.

Read More

Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer

12 January 2021

Artios Pharma, a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announces the appointment of Abid Ansari as Chief Financial Officer (CFO).

Read More

PetMedix partners with Boehringer Ingelheim

12 January 2021

PetMedix is pleased to announce a multi-year partnership with Boehringer Ingelheim to develop novel and transformative companion animal antibody therapeutics using PetMedix's proprietary Ky9™ platform.

Read More